DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9rkkb5/therapy_trends) has announced the addition of the "Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification" report to their offering.

In 2012, the Alzheimer's disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J's bapineuzumab and the intravenous formulation of the drug was discontinued. Expectations for beta-amyloid theory were low following this failure; however results from Eli Lilly's solanezumab have offered a glimmer of hope for the AD community. Although missing its primary endpoints, pooled analysis of solanezumab data in mild patients showed a statistical significant slowdown of cognitive decline.

With novel therapies slowly emerging from the pipeline, such as beta secretase and tau therapies, and positive research into biomarkers to aid early AD diagnosis there is renewed hope as the market enters a new phase of development.

Therapy Trends: Alzheimer's Disease' is compiled from exclusive, in-depth interviews with the world's leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.

Reasons To Buy

- Comprehend the current trends driving and shaping the global AD market

- Understand the future landscape and how new classes will fit into the treatment algorithm

- Assess the commercial and clinical potential of the pipeline beta-amyloid and BACE inhibitors

- Develop planning strategies based from KOL insight

Read the rest here:
Research and Markets: Therapy Trends: Alzheimer's Disease - Breaking New Ground in Disease Modification

Comments are closed.